Notice

The database server is currently not answering requests properly. Some pages are still available due to caching. We are investigating the situation and will keep you updated.

CRISPR-engineered T cells in patients with refractory cancer

Journal: Science

Published: 2020-02-28

DOI: 10.1126/science.aba7365

Affiliations: 12

Authors: 41

Go to article
Institutions Share
Center for Cellular Immunotherapies (CCI), Penn, United States of America (USA) 0.53
Department of Pathology and Laboratory Medicine, Penn, United States of America (USA) 0.10
Department of Microbiology, Penn, United States of America (USA) 0.07
Division of Hematology and Oncology, Penn Medicine, United States of America (USA) 0.06
Abramson Cancer Center, Penn, United States of America (USA) 0.06
Stanford Center for Personal Dynamic Regulomes (CPDR), United States of America (USA) 0.05
Stanford Department of Pathology, United States of America (USA) 0.04
Parker Institute for Cancer Immunotherapy, United States of America (USA) 0.03
Department of Neurology, Penn, United States of America (USA) 0.02
Department of Biostatistics, Epidemiology and Informatics (DBEI), Penn, United States of America (USA) 0.02
Department of Orthopaedic Surgery, Penn, United States of America (USA) 0.01
Stanford School of Medicine, United States of America (USA) 0.01

Return

Except where otherwise noted © 2020 Springer Nature Limited. All Rights Reserved.
partner of AGORA, HINARI, OARE, INASP, ORCID, CrossRef and COUNTER